Expertise in

conditions

Nicolaus M. Kroger

Uke

Hamburg, HH, DE

Expertise in

conditions

Uke

Hamburg, HH, DE

Overview

Nicolaus Kroger practices practicing medicine in Hamburg, Germany.

Kroger is highly rated in 36 conditions, according to our data. Their clinical expertise encompasses Graft Versus Host Disease (GvHD), Myelofibrosis, Leukemia, Bone Marrow Transplant, and Bone Graft.

They are actively involved in clinical research, co-authoring 800 peer reviewed articles and participating in 9 clinical trials.

Locations

UKE
Hamburg, HH 20246, Germany

Other Locations

Ferdinand Sauerbruch Str, Greifswald, MV 17475, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Enrollment Status: Completed

Publish Date: December 01, 2025

Intervention Type: Biological, Drug

Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine

Study Phase: Phase 3

Enrollment Status: Active_not_recruiting

Publish Date: April 22, 2025

Intervention Type: Drug

Study Phase: Phase 2

Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug, Procedure

Study Drug: Ruxolitinib continuous therapy

Study Phase: Phase 2

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma. A Phase II Study (Allo-MM-PostCy-Study)

Enrollment Status: Completed

Publish Date: March 30, 2025

Intervention Type: Drug

Study Drug: Cyclophosphamide

Study Phase: Phase 2

IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation

Enrollment Status: Completed

Publish Date: September 19, 2024

Intervention Type: Drug

Study Drug: Enasidenib

Study Phase: Phase 2

Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability

Enrollment Status: Completed

Publish Date: October 27, 2023

Intervention Type: Procedure

Study Phase: Phase 2

A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)

Enrollment Status: Terminated

Publish Date: March 16, 2022

Intervention Type: Drug

Study Phase: Phase 2

TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia

Enrollment Status: Terminated

Publish Date: June 22, 2021

Intervention Type: Genetic, Other

Study Phase: Phase 3

Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease

Enrollment Status: Terminated

Publish Date: January 30, 2020

Intervention Type: Biological

Study Phase: Phase 3

View 8 Less Clinical Trials

800 Total Publications

Comparison of Fludarabine/Treosulfan Conditioning with Melphalan-Based Sequential Conditioning in Patients with MDS and Increased Blasts Undergoing Upfront Transplantation.

Journal: Cancers

Published: October 02, 2026

View All 800 Publications

Frequently Asked Questions about Nicolaus M. Kroger

Is Nicolaus M. Kroger a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Nicolaus M. Kroger is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nicolaus M. Kroger participate in research or clinical trials?

Yes. Nicolaus M. Kroger has published 800 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Nicolaus M. Kroger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kroger's expertise for a condition

ConditionClose